Prevalence and clinical consequences of Hepatitis E in patients who underwent liver transplantation for chronic Hepatitis C in the United States

Ludi Koning, Michael R. Charlton, Suzan D. Pas, Julie K. Heimbach, Albert D M E Osterhaus, Kymberly D. Watt, Harry L A Janssen, Robert J. de Knegt, Annemiek A. van der Eijk

Research output: Contribution to journalArticle

12 Citations (Scopus)

Abstract

Background: Infection with hepatitis E virus (HEV) in immunocompromised patients can lead to severe liver disease. Treatment options for HEV include peginterferon or ribavirin, routinely also used for the treatment of hepatitis C virus (HCV) infection. We determined the prevalence and clinical consequences of HEV in United States (US) based patients who underwent liver transplantation (LT) for chronic HCV. Methods: Seroprevalence of HEV in 145 US LT recipients with a history of chronic HCV was determined pre-LT, 1, 3 and 5 years post-LT. All last available samples and all samples in IgM positive patients and post-LT IgG seroconverters were tested for HEV RNA. Results: Overall anti-HEV seroprevalence was 42 %. Five patients were HEV IgM positive pre-LT, one patient had IgM seroconversion post-LT and eight patients had IgG seroconversion post-LT. None of the tested samples were positive for HEV RNA. Eight out of nine of the post-LT seroconverters had been treated for HCV recurrence before or at the moment of seroconversion. Conclusions: LT recipients in the US are at risk of acquiring HEV. Post-LT HCV treatment with interferons and/or ribavirin may have protected patients against chronic HEV. With the arrival of new direct antiviral agents for the treatment of HCV and the elimination of peginterferon and ribavirin from HCV treatment regimens, the prevalence of chronic HEV in this population may rise again.

Original languageEnglish (US)
Article number371
JournalBMC Infectious Diseases
Volume15
Issue number1
DOIs
StatePublished - Sep 2 2015

Fingerprint

Hepatitis E
Hepatitis E virus
Chronic Hepatitis C
Liver Transplantation
Hepacivirus
Ribavirin
Immunoglobulin M
Seroepidemiologic Studies
Chronic Hepatitis
Immunoglobulin G
RNA
Therapeutics
Immunocompromised Host
Virus Diseases
Interferons
Antiviral Agents
Liver Diseases

ASJC Scopus subject areas

  • Infectious Diseases

Cite this

Koning, L., Charlton, M. R., Pas, S. D., Heimbach, J. K., Osterhaus, A. D. M. E., Watt, K. D., ... van der Eijk, A. A. (2015). Prevalence and clinical consequences of Hepatitis E in patients who underwent liver transplantation for chronic Hepatitis C in the United States. BMC Infectious Diseases, 15(1), [371]. https://doi.org/10.1186/s12879-015-1103-9

Prevalence and clinical consequences of Hepatitis E in patients who underwent liver transplantation for chronic Hepatitis C in the United States. / Koning, Ludi; Charlton, Michael R.; Pas, Suzan D.; Heimbach, Julie K.; Osterhaus, Albert D M E; Watt, Kymberly D.; Janssen, Harry L A; de Knegt, Robert J.; van der Eijk, Annemiek A.

In: BMC Infectious Diseases, Vol. 15, No. 1, 371, 02.09.2015.

Research output: Contribution to journalArticle

Koning, L, Charlton, MR, Pas, SD, Heimbach, JK, Osterhaus, ADME, Watt, KD, Janssen, HLA, de Knegt, RJ & van der Eijk, AA 2015, 'Prevalence and clinical consequences of Hepatitis E in patients who underwent liver transplantation for chronic Hepatitis C in the United States', BMC Infectious Diseases, vol. 15, no. 1, 371. https://doi.org/10.1186/s12879-015-1103-9
Koning, Ludi ; Charlton, Michael R. ; Pas, Suzan D. ; Heimbach, Julie K. ; Osterhaus, Albert D M E ; Watt, Kymberly D. ; Janssen, Harry L A ; de Knegt, Robert J. ; van der Eijk, Annemiek A. / Prevalence and clinical consequences of Hepatitis E in patients who underwent liver transplantation for chronic Hepatitis C in the United States. In: BMC Infectious Diseases. 2015 ; Vol. 15, No. 1.
@article{c180a1ec962744a0a73ecc373ec2ae9f,
title = "Prevalence and clinical consequences of Hepatitis E in patients who underwent liver transplantation for chronic Hepatitis C in the United States",
abstract = "Background: Infection with hepatitis E virus (HEV) in immunocompromised patients can lead to severe liver disease. Treatment options for HEV include peginterferon or ribavirin, routinely also used for the treatment of hepatitis C virus (HCV) infection. We determined the prevalence and clinical consequences of HEV in United States (US) based patients who underwent liver transplantation (LT) for chronic HCV. Methods: Seroprevalence of HEV in 145 US LT recipients with a history of chronic HCV was determined pre-LT, 1, 3 and 5 years post-LT. All last available samples and all samples in IgM positive patients and post-LT IgG seroconverters were tested for HEV RNA. Results: Overall anti-HEV seroprevalence was 42 {\%}. Five patients were HEV IgM positive pre-LT, one patient had IgM seroconversion post-LT and eight patients had IgG seroconversion post-LT. None of the tested samples were positive for HEV RNA. Eight out of nine of the post-LT seroconverters had been treated for HCV recurrence before or at the moment of seroconversion. Conclusions: LT recipients in the US are at risk of acquiring HEV. Post-LT HCV treatment with interferons and/or ribavirin may have protected patients against chronic HEV. With the arrival of new direct antiviral agents for the treatment of HCV and the elimination of peginterferon and ribavirin from HCV treatment regimens, the prevalence of chronic HEV in this population may rise again.",
author = "Ludi Koning and Charlton, {Michael R.} and Pas, {Suzan D.} and Heimbach, {Julie K.} and Osterhaus, {Albert D M E} and Watt, {Kymberly D.} and Janssen, {Harry L A} and {de Knegt}, {Robert J.} and {van der Eijk}, {Annemiek A.}",
year = "2015",
month = "9",
day = "2",
doi = "10.1186/s12879-015-1103-9",
language = "English (US)",
volume = "15",
journal = "BMC Infectious Diseases",
issn = "1471-2334",
publisher = "BioMed Central",
number = "1",

}

TY - JOUR

T1 - Prevalence and clinical consequences of Hepatitis E in patients who underwent liver transplantation for chronic Hepatitis C in the United States

AU - Koning, Ludi

AU - Charlton, Michael R.

AU - Pas, Suzan D.

AU - Heimbach, Julie K.

AU - Osterhaus, Albert D M E

AU - Watt, Kymberly D.

AU - Janssen, Harry L A

AU - de Knegt, Robert J.

AU - van der Eijk, Annemiek A.

PY - 2015/9/2

Y1 - 2015/9/2

N2 - Background: Infection with hepatitis E virus (HEV) in immunocompromised patients can lead to severe liver disease. Treatment options for HEV include peginterferon or ribavirin, routinely also used for the treatment of hepatitis C virus (HCV) infection. We determined the prevalence and clinical consequences of HEV in United States (US) based patients who underwent liver transplantation (LT) for chronic HCV. Methods: Seroprevalence of HEV in 145 US LT recipients with a history of chronic HCV was determined pre-LT, 1, 3 and 5 years post-LT. All last available samples and all samples in IgM positive patients and post-LT IgG seroconverters were tested for HEV RNA. Results: Overall anti-HEV seroprevalence was 42 %. Five patients were HEV IgM positive pre-LT, one patient had IgM seroconversion post-LT and eight patients had IgG seroconversion post-LT. None of the tested samples were positive for HEV RNA. Eight out of nine of the post-LT seroconverters had been treated for HCV recurrence before or at the moment of seroconversion. Conclusions: LT recipients in the US are at risk of acquiring HEV. Post-LT HCV treatment with interferons and/or ribavirin may have protected patients against chronic HEV. With the arrival of new direct antiviral agents for the treatment of HCV and the elimination of peginterferon and ribavirin from HCV treatment regimens, the prevalence of chronic HEV in this population may rise again.

AB - Background: Infection with hepatitis E virus (HEV) in immunocompromised patients can lead to severe liver disease. Treatment options for HEV include peginterferon or ribavirin, routinely also used for the treatment of hepatitis C virus (HCV) infection. We determined the prevalence and clinical consequences of HEV in United States (US) based patients who underwent liver transplantation (LT) for chronic HCV. Methods: Seroprevalence of HEV in 145 US LT recipients with a history of chronic HCV was determined pre-LT, 1, 3 and 5 years post-LT. All last available samples and all samples in IgM positive patients and post-LT IgG seroconverters were tested for HEV RNA. Results: Overall anti-HEV seroprevalence was 42 %. Five patients were HEV IgM positive pre-LT, one patient had IgM seroconversion post-LT and eight patients had IgG seroconversion post-LT. None of the tested samples were positive for HEV RNA. Eight out of nine of the post-LT seroconverters had been treated for HCV recurrence before or at the moment of seroconversion. Conclusions: LT recipients in the US are at risk of acquiring HEV. Post-LT HCV treatment with interferons and/or ribavirin may have protected patients against chronic HEV. With the arrival of new direct antiviral agents for the treatment of HCV and the elimination of peginterferon and ribavirin from HCV treatment regimens, the prevalence of chronic HEV in this population may rise again.

UR - http://www.scopus.com/inward/record.url?scp=84940480466&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=84940480466&partnerID=8YFLogxK

U2 - 10.1186/s12879-015-1103-9

DO - 10.1186/s12879-015-1103-9

M3 - Article

C2 - 26328802

AN - SCOPUS:84940480466

VL - 15

JO - BMC Infectious Diseases

JF - BMC Infectious Diseases

SN - 1471-2334

IS - 1

M1 - 371

ER -